Although many anti cancer therapies are successful in killing a large percentage of tumour cells when initially administered, the evolutionary dynamics underpinning tumour progression mean that often resistance is an inevitable outcome, allowing for new tumour phenotypes to emerge that are unhindered by the therapy. Research in the field of ecology suggests that an evolutionary double bind could be an effective way to treat tumours. In an evolutionary double bind two therapies are used in combination such that evolving resistance to one leaves individuals more susceptible to the other. In this paper we present a general evolutionary game theory model of a double bind to study the effect that such approach would have in cancer. Furthermore we use this mathematical framework to understand recent experimental results that suggest a synergistic effect between a p53 cancer vaccine and chemotherapy. Our model recapitulates the experimental data and provides an explanation for its effectiveness based on the commensalistic relationship between the tumour phenotypes.
Introduction
Cancer is known to be an evolutionary disease [1] . One of the most negative aspects of the evolutionary nature of cancer is that tumours can evolve resistance to anti-cancer treatments. It has recently been suggested that we should consider therapies that exploit evolutionary dynamics rather than fail because of them. One such therapy maybe to exploit an evolutionary double bind, which in the context of cancer can be understood as a therapy in which adaptation to it represents a significant fitness cost [2] . This cost could represent a number of things, such as a lower proliferation rate to minimise exposure to drugs that target mitosis, the realocation of resources away from proliferation in order to obtain resistance or switching to alternative less efficient pathways that are not targeted. Combination therapies, by which more than one treatment is administered have the potential to hinder the evolution of resistance as tumours need to adapt to each treatment independently and resistance to one treatment might make resistance to the other more difficult.
In this sense combination therapies are potentially an ideal approach to facilitate an evolutionary double bind, where adaptation to one treatment would leave resistant tumour cells more susceptible to another treatment than the original population.
Its generally well accepted now that cancer consists of multiple populations that are phenotypically (and genotypically) distinct. This inherent heterogeneity that all cancers appear to exhibit is one of the central reasons why resistance emerges in the first place. Since a mono-clonal population that consisted of phenotypically identical cells would be far easier to target therapeutically than one that consists of a heterogeneous mix of many competing phenotypes. Also, such heterogeneity could allow for preexisting resistance as opposed to de novo resistance. Regardless of the precise mechanism of resistance, reducing heterogeneity in a cancer population should make it a more treatable disease. However, we must be cautious as treatments that manipulate this heterogeneity may select more aggressive phenotype rather than weaker ones [3] . If it is possible to exploit an evolutionary double bind we will naturally circumvent this problem.
In this paper we introduce a general theoretical framework to study the potential of evolutionary double binds based on combination therapies as a cancer treatment. This framework uses evolu-tionary game theory (EGT), a mathematical tool that has been traditionally used in evolutionary ecology [4] and more recently in mathematical oncology [5, 6, 7, 8, 9, 10] . This modelling tool has potential to provide insights into the evolutionary dynamics of cancer when a combination therapy is used. Importantly EGT can help explore the role of tumour cell interactions in the emergence of resistance. More specifically we have utilized an EGT model to understand how chemotherapy can improve the efficacy of a p53 vaccine as has been reported by Antonia, Gabrilovich and colleagues[11, 12].
A general model of an evolutionary double bind
We consider three different populations and two different treatments. For simplicity the treatments will be referred to as A and B. The populations are S, susceptible to both treatments, R A that is completely resistant to treatment A but susceptible to treatment B and R B that is resistant to treatment B and susceptible to treatment A. The cost of resistant is determined by c A and c B and is assumed to be a fixed cost affecting the fitness of the phenotypes R A and R B respectively. The cost of treatment A to those phenotypes that are non resistant (i.e.: S and R B ) is a function of time, d A , that is a given constant value when the drug is applied and zero when it is not. The drug B has been modelled in the same way but affecting only S and R A . The total population is made of these three phenotypes with a proportion p A of drug A resistant cells, p B of drug B resistant cells and the rest made of susceptible cells. Under these assumptions, the following equations represent the fitness of each of the subpopulations:
Where α and β represent the extra cost of a resistant phenotype being subjected to a different drug. These constants capture the double bind aspect of the model, since a phenotype resistant to one drug can be more susceptible to the other.
Given that the average fitness (W ) in the population can be defined as:
the proportion p of a given phenotype i in the tumour population at a given time t then will be given by:
This model assumes that interactions between these populations have no impact on the evolution of resistance but arguably, the fitness of each of these three populations could change as a result of those interactions. For instance, assuming that space and nutrients are scarce, a resistant phenotype interacting with susceptible cells will be better off than the same cell interacting with equally resistant cells as in the first case it would have easier access to nutrients and space required for proliferation. This and other hypothetical mechanisms for resistance, like paracrine ones that could affect phenotypes that do not produce them, could be further explored with a matrix based approach. Using a matrix approach we can explore how the interactions between different phenotypes impacts their fitness. The following table enhances the previously described model by describing how interactions between phenotypes influence the susceptibility of cells to treatments and thus potentially improve their fitness: 
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For simplicity we left α and β as constants and equal to 1.1. The treatments d I (t) and d C (t) are Heaviside step functions multiplied by a cost in the range [0:1]. This value and the duration of the step will be variables to characterise the treatment. Under these circumstances the average tumour cell fitness is the following:
(1.4)
How timing affects the effectiveness of the treatment
We first validated the mathematical model using the results published by Antonia and colleagues [11, 12] . Figure 1 .2 shows the difference in results when chemotherapy is applied first in contrast to when it is applied second. In the first case (1.2 top left) the p53 vaccine is administered first which results in an steady increase of the I population and a dramatic reduction of the S population.
After 60 timesteps the p53 vaccine stops being active and chemotherapy is applied after which the tumour almost entirely consists of C cells. In the second case (1.2 top right) the first treatment is chemotherapy which selects for C cells driving the other two populations towards extinction. The benefit, of course, in using a simple mathematical model to investigate these dynamics is that we can explore a variety of protocols characterised by order, intensity and duration both quickly and cheaply allowing us to easily determine which protocols are the most effective. In order to gain a better a better understanding of the evolution of the tumour under these treatments we studied in more detail a number of scenarios. 
Discussion: reducing heterogeneity
We have developed a general model of the evolutionary double bind and applied this model to investigate the role a double bind might play in a combination therapy involving chemotherapy and a p53 vaccine. The model is general enough that it could be used to study evolutionary dynamics of double bind in the context of somatic evolution (as well as other evolutionary contexts). The model is also simple requiring only a few parameters that characterise, the cost of resistance to the vaccine and chemotherapy, the cost of susceptibility to either therapy and the cost/benefit of susceptible cells interacting with resistant ones when a given treatment is administered. The results show that the model readily recapitulates the observed experimental behaviour when using combination therapies based on immuno-and chemo-therapies. However, the model can delve deeper into the treatment dynamic and predicts how different scheduling and dosage will impact tumour heterogeneity and fitness. As with all mathematical models, a number of caveats apply: we assume a homogeneously mixed population. We assume only three relevant tumour subpopulations and that these populations do not change over time (e.g. by become more efficient at being resistant).
Given the timescales involved (days to weeks) it is unlikely that new genetic mutations would allow the existing populations to change their phenotype significantly.
Despite its simplicity, the model illustrates the importance of understanding the role of cell-cell interactions in cancer. Usually these interactions are understood to be competitive in nature but the types of interactions in a tumour can be more complex than that [14] . In the combination therapy example (p53 vaccine and chemotherapy) the relationship between the susceptible and chemoresistant phenotypes on one hand and the p53 vaccine resistant phenotype on the other seems to correspond to a comensalistic relationship by which the latter provides some degree of protection against the immune system for the former without receiving any reward for that service. If the cost of the p53 vaccine is moderate (0.2) then susceptible populations will have a chance to survive and thus to recover when the vaccine is no longer active. If we increase this cost (0.3) the chemotherapy resistant population is driven beyond the point of recovery, so when chemotherapy is applied all the remaining populations are susceptible. Nonetheless, if we further increase the cost (0.4) the result is that the population that disappears during the application of the vaccine is the sensitive one whereas the chemotherapy resistant, while minimal, is still there. Once the treatment is switched to chemotherapy it will recover driving up the overall tumour fitness.
The model shows how the order in which the treatments are applied is important. It also suggests that the amount of time that chemotherapy is active is more important than that of the p53 vaccine.
With regards to protocols where the p53 vaccine is applied first, the results suggest that treatments where the vaccine has a long term effect on the tumour are more likely to be effective in impacting the fitness of the tumour. Although protocols that use the p53 vaccine first are usually not as effective as those that use chemotherapy first they both have in common that the first treatment should be effective for as long as possible to be efficacious. This is because the role of the first treatment should be to reduce the heterogeneity of the tumour in order to diminish the chances of the tumour evolving resistance. In the EGT model we presented here, its no accident that we equate directly tumour fitness and tumour heterogeneity. By reducing heterogeneity (i.e. in this context, knocking out one of the resistant populations) with the first treatment we can apply a suitably targeted second treatment to knock out the remaining resistant populations. Unfortunately, the reality might be that there are multiple subpopulations that would require different drug or treatment strategies to eradicate them all and of course this is simply impractical. However, if we can harness the power of strategies such as the evolutionary double bind we may exploit synergistic aspects of multiple treatments and manage to drive the tumour population to extinction even with highly heterogenous tumours.
The general model we have described here can be used to study other situations where resistance to a given treatment comes at a cost and where the interactions between tumour cell populations are important with regards to their susceptibility to a therapy. A key advantage of the model is its ability to quickly and easily test multiple combinations of treatments under different schedules and doses and highlight which should be chosen for experimental testing. This integrated approach to cancer treatment will not only allow for the development of potentially novel therapies but simultaneously allow them to be targeted and optimized for a given patient. Critical to this integration, however,
is the feedback between model and experiment. Thus future application of this model must involve direct collaboration with experimentalists in order to properly parameterise and test model driven hypothesis. by immature myeloid cells, the induction of antiadenoviral immune responses, etc. In one study, it was not possible to evaluate all possible mechanisms. Our analysis indicated that inhibition of overall T cell reactivity and accumulation of T reg were not associated with failure to develop p53-specific immune responses. Our data do not necessarily indicate a lack of involvement of T reg in SCLC. T reg may migrate from peripheral blood to the site of the tumors. In addition, because all patients were treated with platinum-based chemotherapy 8 weeks before the analysis, it is possible that chemotherapy could have eliminated some of these cells as was previously reported for cyclophosphamide (34). Investigation is currently under way to address this issue.
Our data showed a trend in the association between a decreased presence of mature CD83 + DCs in the peripheral blood of patients prior to vaccination and a lack of immune response to the vaccine. These data may point out an important role of host DCs in the development of antigen-specific immune responses. Nearly all patients enrolled in the trial had significantly reduced levels of DC function, suggesting that improvement of DC function prior to vaccination might be necessary to achieve improved efficacy of the vaccine.
Patients with ES SCLC had increased levels of immature myeloid cells, the cells implicated in tumor-associated antigenspecific immune suppression (21, 22, 35). Importantly, 100% of patients with normal prevaccine levels of immature myeloid Three simulations where the p53 vaccine is applied first using three different penalties for cells susceptible to the p53 vaccine Left 0.2. Application of the p53 vaccine results in a strong selection force for tumour cells that are resistant. After 75 time steps the application of chemotherapy results in a strong growth for the chemotherapy resistant population which was never entirely eradicated. Centre 0.3. As it was the case before, the first 75 time steps result in selection of p53 vaccine resistant cells but in this case the chemotherapy resistant population has been decimated to the extent that is unable to show any noticeable recovery when chemotherapy is applied. The original population susceptible to the two treatments, although not entirely eradicated is unable to play a role. Right 0.4. As it was the case previously, after the 75 time steps of p53 vaccine chemotherapy is applied. In this case the original susceptible population is entirely eradicated whereas the one that is resistant to chemotherapy, although comparatively very small, manages to survive until the application of chemotherapy results in a strong selection force for this cell type.Bottom The average tumour fitness under the three different scenarios. 
